Androgen Deprivation Therapy Industry Growth Outlook: 6% CAGR and $10.49 Billion by 2029

Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments._x000D_
_x000D_
What Is the Long-Term Growth Forecast for the Androgen Deprivation Therapy Market Size 2025?_x000D_
Over the past several years, the androgen deprivation therapy market has experienced a significant increase in its size. It is projected to expand from $7.81 billion in 2024 to $8.31 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.3%. The growth witnessed in the historical period was influenced by factors such as the increased global occurrence of prostate cancer, a rise in the elderly male population, high prostate cancer relapse rates, better survival rates promoting long-term treatment, and heightened consciousness regarding early screening for prostate cancer._x000D_
_x000D_
What CAGR is Forecasted for the Androgen Deprivation Therapy Market Through 2029?_x000D_
The market for androgen deprivation therapy is predicted to flourish significantly in the upcoming years, rising to $10.49 billion in 2029 with a compound annual growth rate (CAGR) of 6.0%. This anticipated growth in the forecast period is due to the increased utilisation of combined therapies in oncology, growing incidence of hormone-sensitive cancers, a surge in diagnosed cases of both localized and advanced prostate cancer, wider application of ADT in non-oncology hormone conditions, and a rising trend of patients opting for non-invasive treatments. Key trends expected in the forecast period are improvements in depot formulations and delivery methods, the emergence of oral ADT medication, the advent of long-acting ADT injectables, the introduction of innovative androgen receptor inhibitors, and tech-driven advancements in digital pathology and diagnostics._x000D_
_x000D_
Explore The Complete Report Now: _x000D_
https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report_x000D_
_x000D_
What Are the Critical Factors Driving Androgen Deprivation Therapy Market Development?_x000D_
The anticipated rise in prostate cancer instances is predicted to boost the expansion of the androgen deprivation therapy market in the foreseeable future. Originating in the prostate gland, which is a part of the male reproductive system that produces seminal fluid, the occurrence of prostate cancer is primarily increasing due to extended life expectancies, as advancing age significantly increases susceptibility to the disease. Androgen deprivation therapy (ADT), the principal treatment approach for prostate cancer, is designed to reduce androgen levels that stimulate tumor growth. It is commonly employed in advanced or metastatic stages to slow down disease progression. For instance, Prostate Cancer UK, a prominent research, awareness, and support organization based in the UK, reported in January 2025 that the number of prostate cancer diagnoses in England had surged from 50,751 cases in 2022 to 55,033 cases in 2023, marking a notable annual increase. Thus, the escalating incidence of prostate cancer is propelling the growth of the androgen deprivation therapy market._x000D_
_x000D_
Get Free Sample Report Here:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp_x000D_
_x000D_
How Does the Androgen Deprivation Therapy Market Break Down Across Major Segments?_x000D_
The androgen deprivation therapy market covered in this report is segmented - _x000D_
_x000D_
1) By Type: Medicine, Surgery, Other Types_x000D_
2) By Route Of Administration: Injectable, Oral_x000D_
3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75_x000D_
4) By Application: Prostate Cancer, Other Applications_x000D_
5) By End-User: Hospitals, Specialty Clinics, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies_x000D_
2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy_x000D_
3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU_x000D_
_x000D_
What Are the Major Trends Transforming the Androgen Deprivation Therapy Industry?_x000D_
Key players in the androgen deprivation therapy market are prioritizing the creation of advanced therapies, such as combined treatments, to enhance the effectiveness of advanced prostate cancer treatments. A combination therapy employs multiple modes of treatment, like hormone therapy in conjunction with chemotherapy, aiming to increase efficiency while slowing disease advancement. For example, Bayer AG, a life sciences organization based in Germany, gained the U.S. Food and Drug Administration's approval in August 2022 for the additional use of darolutamide together with docetaxel to treat metastatic hormone-responsive prostate cancer (mHSPC). The recently approved combination therapy focuses on improving survival rates and slowing disease progression in people diagnosed with metastatic hormone-responsive prostate cancer (mHSPC), which is a scenario where the cancer has metastasised but continues to be responsive to hormone treatments. The therapy stands out due to the inclusion of darolutamide, an orally administered medication that directly targets androgen receptors. Its distinct molecular structure allows for a strong bond with these receptors. Consequently, this effectively halts their functionality, leading to an inhibition in the growth and proliferation of prostate cancer cells._x000D_
_x000D_
Customize Your Insights And Get The Full Report Here:_x000D_
https://www.thebusinessresearchcompany.com/customise?id=25692&type=smp_x000D_
_x000D_
Which Players Are Driving Innovation in the Androgen Deprivation Therapy Market?_x000D_
Major companies operating in the androgen deprivation therapy market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen S.A., Dr. Reddy's Laboratories Ltd., Orion Corporation, Arvinas Inc., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc., Lawley Pharmaceuticals Pty Ltd. _x000D_
_x000D_
Which Regions Are Driving Global Androgen Deprivation Therapy Market Expansion?_x000D_
North America was the largest region in the androgen deprivation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out to Us#_x000D_
_x000D_
Speak With Our Expert: _x000D_
Saumya Sahay _x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email: saumyas@tbrc.info_x000D_
_x000D_
The Business Research Company - www.thebusinessresearchcompany.com_x000D_
_x000D_
Follow Us On:_x000D_
• LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
_x000D_

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.